Table 3.
Mount Sinai cohort |
Geisinger cohort |
|||
---|---|---|---|---|
Unadjusted (95% CI) | Adjusted (95% CI) | Unadjusted (95% CI) | Adjusted (95% CI) | |
Using AKIKDIGO definition | 0.4 (0.2–0.7) | 0.4 (0.2–0.7) | 0.5 (0.3–0.8) | 0.6 (0.4–1.1) |
Using AKI ICD codes | 0.5 (0.3–0.8) | 0.5 (0.3–0.9) | 0.43 (0.23–0.79) | 0.56 (0.27–1.16) |
User/nonusers not missing any covariate data | 0.7 (0.3–1.3) | 0.7 (0.3–1.4) | 0.70 (0.37–1.33) | 0.81 (0.40–1.66) |
Canagliflozin | 0.2 (0.1–0.5) | 0.2 (0.1–0.5) | 0.54 (0.32–0.93) | 0.61 (0.33–1.12) |
Dapagliflozin | 1.0 (0.5–2.4) | 1.1 (0.5–2.7) | 0.16 (0.02–1.33) | 0.32 (0.02–5.18) |
Empagliflozin | NA | NA | 0.50 (0.15–1.66) | 0.96 (0.21–4.35) |
Results for empagliflozin in Mount Sinai cohort not available (NA) because of small sample size and lack of model convergence.